کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3348287 1216006 2007 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله
Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries
چکیده انگلیسی
The Zyvox® Annual Appraisal of Potency and Spectrum Program has completed its fifth year of monitoring for emerging resistance to linezolid and other Gram-positive active agents on the continents of Europe, Asia, Australia, and Latin America. In 2006, 4216 Gram-positive isolates from 16 nations were submitted for analysis from 6 organism groups including Staphylococcus aureus (54.0%), coagulase-negative staphylococci (CoNS) (14.6%), enterococci (10.0%), Streptococcus pneumoniae (9.4%), viridans group streptococci (5.0%), and β-hemolytic streptococci (7.0%). Linezolid retained potent activity against S. aureus (MIC50 and MIC90, 2 μg/mL; 39.8% methicillin resistant) and CoNS (MIC50 and MIC90, 1 μg/mL; 74.3% methicillin resistant). Despite endemicity of vancomycin-resistant enterococci (up to 30.0%) in several nations, linezolid inhibited >99% of strains at ≤2 μg/mL (modal MIC, 1 μg/mL). Among streptococci, all linezolid MIC values were ≤2 μg/mL. Rare instances of linezolid-resistance were detected in enterococci (2 isolates, China and Germany) and CoNS (3 isolates, Italy and Brazil); 2 CoNS and 1 Enterococcus faecium had documented G2576T mutations. Overall, linezolid remained active against 99.88% of tested strains from this global collection.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Diagnostic Microbiology and Infectious Disease - Volume 59, Issue 2, October 2007, Pages 199-209
نویسندگان
, , , ,